Biocryst Pharmaceuticals INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
BioCryst Pharmaceuticals achieved significant revenue growth and profitability in 2025, driven by ORLADEYO sales and strategic acquisitions, while expanding its rare disease pipeline.
NASDAQ
BioCryst Pharmaceuticals reports strong ORLADEYO sales growth and pipeline progress in its 2024 10-K filing, highlighting its focus on rare diseases and profitability.
NASDAQ
BioCryst Pharmaceuticals' 2023 annual report details financial performance and advancements in its rare disease drug pipeline, including ORLADEYO and BCX10013.